Gummy bears for baldness? new study tests sweet solution

NCT ID NCT07637071

Not yet recruiting Disease control Sponsor: Restore Biologics Holdings, Inc. dba Xtressé Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study will test whether a daily gummy supplement called Xtressé can safely improve hair growth in 40 men with male pattern baldness. Participants take two gummies each day for six months, and researchers measure changes in hair density and thickness using special cameras. The study is small and has no placebo group, so results will be preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Xtressé Hair Growth Gummies (proprietary X-3 BioActive Blend with plant extracts and regenerative compounds)
What this could lead to: If it works, this could point toward a convenient, daily supplement option to help men with hair thinning improve hair density and thickness.
What could go wrong: This is a very small pilot study (40 men) with no placebo group, so results may not be reliable or generalizable. The supplement is not a drug and may have limited or no effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANDROGENIC ALOPECIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia androgenetic alopecia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANDROGENIC ALOPECIA HAIR LOSS/BALDNESS HAIR THINNING

Contacts and locations

Locations

Advanced Dermatology & Cosmetic Surgery

Maitland, Florida, 32751, United States
Advanced Dermatology & Cosmetic Surgery

Port Orange, Florida, 32127, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.